Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood pH

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    607 result(s) found for: Blood pH. Displaying page 7 of 31.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2019-002826-58 Sponsor Protocol Number: 1 Start Date*: 2020-02-05
    Sponsor Name:Rijnstate Hospital, Arnhem
    Full Title: The effects of enoximone in acute exacerbation COPD: a pilot study
    Medical condition: Acute exacerbation of COPD
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003367-26 Sponsor Protocol Number: MK4482-001 Start Date*: 2020-11-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) SE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-006082-11 Sponsor Protocol Number: ADG20-TRMT-001 Start Date*: 2021-06-02
    Sponsor Name:Adagio Therapeutics Inc.
    Full Title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) DE (Prematurely Ended) HU (Completed) BG (Prematurely Ended) PL (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-001083-11 Sponsor Protocol Number: LAL2116 Start Date*: 2016-11-05
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients with Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab
    Medical condition: Acute Lymphoblastic Leukemia Philadelphia Chromosome Positive (Ph+)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004230-40 Sponsor Protocol Number: B1871006 Start Date*: 2006-02-17
    Sponsor Name:Wyeth Pharmaceuticals Inc., a wholly owned subsidary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA
    Full Title: A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias
    Medical condition: Philadelphia Chromosome positive leukemias occur as a result of a reciprocal translocation between chromosomes 9 and 22. Its most common phenotype is Chronic Myelogenous Leukemia (CML), which has ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10034877 Philadelphia chromosome positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) AT (Completed) FI (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005712-27 Sponsor Protocol Number: CA180056 Start Date*: 2007-08-01
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chrom...
    Medical condition: Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) GR (Completed) BE (Completed) NL (Completed) DE (Completed) AT (Completed) HU (Completed) ES (Completed) IT (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002501-22 Sponsor Protocol Number: PHP-303-A201 Start Date*: 2020-05-04
    Sponsor Name:pH Pharma Inc.
    Full Title: A Multi-Center, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Tolerability of the Neutrophil Elastase Inhibitor PHP-303 in Adults with Alpha-1 Antitrypsin Defic...
    Medical condition: Alpha-1 Antitrypsin Deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002853-13 Sponsor Protocol Number: EWALL-BOLD Start Date*: 2018-03-01
    Sponsor Name:Goethe Universität Frankfurt
    Full Title: Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Bli...
    Medical condition: Patient aged 56 and 74 with CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000528-32 Sponsor Protocol Number: TRaffiq Start Date*: 2018-07-12
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar)
    Full Title: Tranexamic acid use to reduce de blood transfusion in femur fracture patients. Clinical randomized trial with placebo control
    Medical condition: Bleeding in patients suffering femur neck fracture
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10053220 Hip injury LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002788-80 Sponsor Protocol Number: Uni-Koeln-4243 Start Date*: 2020-09-09
    Sponsor Name:University of Cologne
    Full Title: An explorative study to assess the safety, tolerability, and efficacy of AZD4831 in the treatment of pulmonary arterial hypertension (PAH) (MPO-PAH)
    Medical condition: Group 1: Pulmonary arterial hypertension (PAH) Group 2: Postcapillary pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001860-27 Sponsor Protocol Number: UoL001542 Start Date*: 2020-05-12
    Sponsor Name:University of Liverpool
    Full Title: AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
    Medical condition: Coronavirus-induced disease (COVID-19) (SARS coronavirus 2, or SARS-CoV-2)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-004808-60 Sponsor Protocol Number: HD-CAR-1/V04 Start Date*: 2018-04-12
    Sponsor Name:University Hospital Heidelberg
    Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial
    Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    23.0 100000004864 10029595 Non-Hodgkin's lymphoma NOS refractory LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019119-39 Sponsor Protocol Number: GIMEMALAL1509 Start Date*: 2011-05-16
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: A multicenter Total Therapy Strategy for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients
    Medical condition: De Novo Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003205-66 Sponsor Protocol Number: MedOPP293 Start Date*: 2022-01-17
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2)
    Medical condition: HER2-Positive Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) IT (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000968-34 Sponsor Protocol Number: CAMN107ADE20 Start Date*: 2015-10-07
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years o...
    Medical condition: The trial aims to evaluate the efficacy and quality of life of nilotinib 300mg BID in patients with chronic myleoid leukemia in chronic phase.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024262-22 Sponsor Protocol Number: CML-V Start Date*: 2012-08-24
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotini...
    Medical condition: chronic phase CML
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014344-11 Sponsor Protocol Number: prot-001-2009 Start Date*: 2010-06-02
    Sponsor Name:Imperial College London
    Full Title: Neuroprotective effects of hypothermia combined with inhaled xenon following perinatal asphyxia - the TOBY Xe trial
    Medical condition: Neonatal asphyxial encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    12 10028946 neonatal hypoxia and asphyxia SOC
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000832-42 Sponsor Protocol Number: n/a Start Date*: 2008-11-05
    Sponsor Name:East Kent Hospital Trust
    Full Title: Effectiveness of Heliox in Hypercapnic Respiratory Failure
    Medical condition: Hypercapnic Respiratory Failure due to excerbation of Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003736-13 Sponsor Protocol Number: CCTL019B2205J Start Date*: 2017-09-29
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
    Medical condition: Paediatric patients with B-cell acute lymphoblastic leukaemia and lymphoma who are refractory, relapsed to prior treatments
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005040-85 Sponsor Protocol Number: HaHes Start Date*: 2006-03-17
    Sponsor Name:Department of Anesthesia, Div. of Cardiothoracic and Vascular Anesthesia, Medical University Vienna
    Full Title: Comparison of Albumin 5%, Hydroxyethyl Starch 130/0.4 (6%) and Ringer Lactate for volume replacement during cardiac surgery
    Medical condition: Intensive care patients after cardiac surgery requiring volume therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 21:03:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA